Clinical Trial: NCT05504707
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | H. Lee Moffitt Cancer Center and Research Institute |
| Information Provided By: | H. Lee Moffitt Cancer Center and Research Institute |
| Last Update Posted: | 2026-02-05 |
Study Overview
Brief Summary
The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.
Official Title
Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)
Conditions
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Intervention / Treatment
- Biological: HER2 - primed Dendritic cells
- Biological: HER3 - primed Dendritic cells
Other Study ID Numbers
- MCC-20897
Start Date (Actual)
2022-08-26
Primary Completion Date (Estimated)
2026-10
Study Completion Date (Estimated)
2026-10
Enrollment (Estimated)
30
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | H. Lee Moffitt Cancer Center and Research Institute |
| Information Provided By: | H. Lee Moffitt Cancer Center and Research Institute |
| Last Update Posted: | 2026-02-05 |
Study Overview
Brief Summary
The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.
Official Title
Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)
Conditions
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Intervention / Treatment
- Biological: HER2 - primed Dendritic cells
- Biological: HER3 - primed Dendritic cells
Other Study ID Numbers
- MCC-20897
Start Date (Actual)
2022-08-26
Primary Completion Date (Estimated)
2026-10
Study Completion Date (Estimated)
2026-10
Enrollment (Estimated)
30
Study Type
Interventional
Phase
Phase 1